Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

15.80
Delayed Data
As of Jun 23
 +0.30 / +1.94%
Today’s Change
8.31
Today|||52-Week Range
32.74
+8.82%
Year-to-Date
Saba Capital Management, L.P. Buys Clough Global Opportunities Fund, General American...
Jun 20 / GuruFocus News - Paid Partner Content
Billionaire John Paulson Wants You to Buy Valeant -- Here's What the Chart Says
Jun 19 / TheStreet.com - Paid Partner Content
John Paulson Joins Valeant's Board During Trying Transition
Jun 20 / GuruFocus News - Paid Partner Content
Valeant Stock Jumps After John Paulson Is Named to Board
Jun 19 / TheStreet.com - Paid Partner Content
Company News for June 20, 2017
Jun 20 / Zacks.com - Paid Partner Content
Valeant (VRX) Down 4% Since Earnings Report: Can It Rebound?
Jun 14 / Zacks.com - Paid Partner Content
John Paulson Joins Valeant's Board to Aid in Trying Transition
Jun 20 / GuruFocus News - Paid Partner Content
Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M
Jun 12 / Zacks.com - Paid Partner Content
John Paulson Joins Valeant's Board to Assist in Trying Transition
Jun 19 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close15.50
Today’s open15.35
Day’s range14.89 - 15.85
Volume37,840,381
Average volume (3 months)22,990,509
Market cap$5.4B
Dividend yield--
Data as of 4:02pm ET, 06/23/2017

Growth & Valuation

Earnings growth (last year)-716.47%
Earnings growth (this year)-34.14%
Earnings growth (next 5 years)-1.55%
Revenue growth (last year)-7.39%
P/E ratioNM
Price/Sales0.52
Price/Book1.74

Competitors

 Today’s
change
Today’s
% change
PTHNPatheon NV+0.05+0.14%
GRFSGrifols SA-0.25-1.11%
UTHRUnited Therapeutics ...-0.11-0.08%
TAROTaro Pharmaceutical ...+2.04+1.79%
Data as of 4:02pm ET, 06/23/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$0.96
Annual revenue (last year)$9.7B
Annual profit (last year)-$2.4B
Net profit margin-24.90%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts